Drug · CHEMBL866
MYCOPHENOLIC ACID
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. MYCOPHENOLIC ACID. Drugs and targets, record CHEMBL866. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL866
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- 68618, Acide mycophenolique, Acido micofenolico, Mycophenolate, Mycophenolate mofetil impurity, mycophenolic acid-, NSC-129185, RS-61443 [AS MOFETIL]
- ChEMBL
Targets2
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| IMPDH1 | Inosine-5'-monophosphate dehydrogenase (IMPDH) | Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor | INHIBITOR | https://conductscience.org/library/genes/3614 |
| IMPDH2 | Inosine-5'-monophosphate dehydrogenase (IMPDH) | Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor | INHIBITOR | https://conductscience.org/library/genes/3615 |
Source ChEMBL
Diseases17
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 17Source Open Targets
See all 17 diseasesTrials78
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 2 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 1 more that Open Targets linked to it is not shown, since the release's checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01950819 | Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM) | Phase 4 | 2,037 | 2019-01-30 | mycophenolic acid | Its name | ClinicalTrials.gov |
| NCT03468478 | Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation | Phase 4 | 1,209 | 2023-04-24 | mycophenolic acid | Its name | ClinicalTrials.gov |
| NCT00251004 | Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients | Phase 3 | 833 | 2011-05-10 | mycophenolic acid | Its name | ClinicalTrials.gov |
| NCT01843348 | 12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients | Phase 3 | 612 | 2017-05-01 | mycophenolic acid | Its name | ClinicalTrials.gov |
| NCT04734197 | A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease | Phase 2 | 349 | 2025-03-18 | mycophenolic acid | Its name | ClinicalTrials.gov |
| NCT01729494 | Belatacept Early Steroid Withdrawal Trial | Phase 4 | 316 | 2021-07-28 | mycophenolic acid | Its name | ClinicalTrials.gov |
| NCT00377962 | Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation | Phase 4 | 282 | 2011-04-18 | mycophenolic acid | Its name | ClinicalTrials.gov |
| NCT00634920 | Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients | Phase 4 | 204 | 2014-08-13 | enteric coated mycophenolate sodium | Open Targets' reading, confirmed by the trial's result groups | ClinicalTrials.gov |
| NCT01625377 | A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant Recipients | Phase 3 | 188 | 2016-04-27 | mycophenolic acid | Its name | ClinicalTrials.gov |
| NCT00862979 | A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients | Phase 4 | 162 | 2018-06-25 | mycophenolic acid | Its name | ClinicalTrials.gov |
1 to 10 of 78
See all 78 trialsComparisons in its trials41
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| EVR+rCNI vs MPA+sCNI: Incidence of Adverse Events, Serious Adverse Events and Adverse Events Leading to Study Regimen Discontinuation. | 276 of 1,014 | 152 of 1,012 | 2,026 | NCT01950819 | Trial comparisons |
| EVR+rCNI vs MPA+sCNI: Incidence of Major Cardiovascular Events. | 66 of 1,014 | 86 of 1,012 | 2,026 | NCT01950819 | Trial comparisons |
| Everolimus Plus@Reduced CNI vs MPA Plus Standard@CNI: deaths from any cause | 20 of 1,014 | 29 of 1,012 | 2,026 | NCT01950819 | Trial comparisons |
| EVR+rCNI vs MPA+sCNI: Incidence of Malignancies. | 41 of 1,014 | 39 of 1,012 | 2,026 | NCT01950819 | Trial comparisons |
| Everolimus Plus@Reduced CNI vs MPA Plus Standard@CNI: serious adverse events | 593 of 1,014 | 613 of 1,012 | 2,026 | NCT01950819 | Trial comparisons |
| Everolimus + CNI Reduction vs Control: Number of Patients With Biopsy-proven Acute Rejection From Month 12 to End of Study (Month 24) | 6 of 108 | 5 of 127 | 235 | NCT00377962 | Trial comparisons |
| Everolimus + CNI Reduction vs Control: Number of Patients in Need of Dialysis From Month 12 to End of Study (Month 24) | 0 of 108 | 2 of 127 | 235 | NCT00377962 | Trial comparisons |
| Tacrolimus vs Everolimus (RAD001): serious adverse events | 28 of 94 | 42 of 90 | 184 | NCT01625377 | Trial comparisons |
| CNI-regimen vs CNI-free-regimen: deaths from any cause | 0 of 84 | 1 of 78 | 162 | NCT00862979 | Trial comparisons |
| CNI-regimen vs CNI-free-regimen: serious adverse events | 40 of 84 | 29 of 78 | 162 | NCT00862979 | Trial comparisons |
1 to 10 of 41
See all 41 comparisons in its trialsPapers from its trials56
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL866
GET https://conductscience.org/api/drugs/v1/CHEMBL866/trials?page=2